a study on Lymphoma
This is a multi-center, phase II study to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory DLBCL.
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Diffuse Large B-cell Lymphoma (DLBCL) Diffuse large B-cell lymphoma, DLBCL, Relapsed/refractory, CTL019 CART19 CART CAR T cells Chimeric antigen receptor
Open to people ages 18 years and up
Histologically confirmed DLBCL at last relapse(by central pathology review before enrolment.
.- Relapsed or refractory disease after ≥2 lines of chemotherapy including rituximab and anthracycline and either having failed autologous Hematopoietic stem cell transplantation (ASCT), or being ineligible for or not consenting to ASCT
Patients with active neurological auto immune or inflammatory disorders(e.g. Guillain Barre Syndrome, Amyptrophic Lateral Sclerosis)
Other protocol-related inclusion/exclusion may apply.
© The Regents of the University of California